How are trial groups compared in a clinical trial?

At several points during the trial, and once more at the end. The comparison is not saved up for the final day, and that matters more than it sounds.

What the two groups actually get

In the simplest design, the investigational group receives the study drug or approach and the control group receives standard treatment. That is the usual setup in cancer research.

Placebos are rarely used in cancer treatment trials. When they are used, you are always told before you decide, and the consent form covers it. NCI describes two situations where a placebo may appear. One is when no standard treatment for that cancer exists. The other is a trial that compares standard treatment plus a placebo against standard treatment plus the study drug. So even in a placebo-controlled cancer trial, you are usually not going untreated. Placebos turn up more often in prevention trials than in treatment trials.

Why the groups have to start out alike

A comparison only means something if the two groups were similar to begin with. Two design features do that work.

The first is the eligibility criteria, the list of requirements for joining. These cut down the medical differences among participants. Results are then more likely to reflect the treatment, and not something else about the people in each group.

The second is randomization. In later-phase trials, people are assigned to groups by chance, usually by a computer. Neither you nor your doctor picks. That guards against bias, which is when results are shaped by human choices instead of by the treatment. Without it, a doctor might steer healthier patients into the new-treatment group without meaning to. That would make the new treatment look better than it is.

Phase 3 trials also enroll large numbers, anywhere from 100 to several thousand people, so a difference between groups is less likely to be a fluke.

What gets compared, and when

Researchers look at two things side by side: how well each approach works, and what side effects each one causes. NCI is specific that these comparisons happen at several points during the trial and at the end, not only at the end.

That running comparison is why some of these studies stop early. A data and safety monitoring board, an independent group of doctors and statisticians, can halt a trial in either direction. If the new treatment is clearly better, stopping early means people outside the trial can reach it sooner. If it is clearly not working, stopping spares people more exposure. The same is true if participants are having unexpected severe side effects. A trial can also end early if too few people enroll, or if another study publishes results that answer the question first.

What this means if you are in one

You will not be handed running results while the trial is open. What you are owed is different: the research team must tell you as new information becomes available, and you can ask questions at any point. You can also leave the trial at any time, even after signing the consent form.

So a trial ending early is not automatically bad news. Ask the study team which reason applied. Stopping for benefit and stopping for lack of benefit lead to very different next steps for your own care. Our explainer on what a control group is covers group assignment, and the piece on clinical trial phases explains why phase 3 is where most comparisons happen.

Sources

• https://www.cancer.gov/research/participate/clinical-trials/how-trials-work
• https://www.cancer.gov/research/participate/clinical-trials/safety